source
- Novartis signs $7.8 billion deal with Abogen for mRNA-encoded autoimmune T-cell engagerNovartis announced it will pay $575 million upfront to Abogen Biosciences for an mRNA-encoded T-cell engager that has shown early clinical activity in autoimmune disease. The agreement includes up…
- BMO sees Merck better positioned than BMS to handle looming patent cliffsBMO Capital Markets says Merck has a stronger plan than Bristol Myers Squibb to replace revenue lost to upcoming patent expirations. The firm highlights Merck's pipeline as more derisked and sizabl…